Aptamer inhibits SARS-CoV-2 with novel mechanism of action, study shows
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
List view / Grid view
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
In this ebook, find articles exploring some of the assays used to identify the most promising COVID-19 drugs and discussing the development of a novel assay to reveal potential peptide therapeutics for cancer.
Researchers have shown that SARS-CoV-2 infects mouth cells, which could inform the development of treatments against the oral symptoms of COVID-19.
Researchers have created an immune assay that can profile host immune responses to infection and is faster than current methods.
A team has shown that tilorone, quinacrine and pyronaridine are effective at inhibiting the replication of SARS-CoV-2 in vitro.
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Researchers have reviewed lung-on-a-chip technologies, finding they are useful for representing the various disease pathologies.
Researchers are using a new method to isolate the complex between SARS-CoV-2 and the ACE2 receptor to keep it embedded in the cell membrane.
Professor Martin Michaelis and Dr Mark Wass explain why new SARS-CoV-2 variants are emerging around the world and how vaccines will have to adapt in response.
Using cryo-electron microscopy, researchers have imaged how the SARS-CoV-2 Spike protein changes with the D614G mutation to enable faster spread of infection.
Researchers have shown that the PLpro coronavirus enzyme presents a possible target in the fight against COVID-19.
SARS-CoV-2 diverts building blocks from glucose production to the assembly of purine bases, researchers have found.
Researchers have shown antibodies induced by the Pfizer and Moderna vaccines are less effective at neutralising certain SARS-CoV-2 variants.
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.